Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BioRay to Start Trials of LIV-1 Targeting ADC for Advanced Malignant Tumors

publication date: May 24, 2023

Shanghai BioRay Pharma will start China trials of BRY812, an ADC that targets human LIV-1, to treat advanced malignant tumors. BRY812 was developed on BioRay's CysLink™ technology platform that offers highly stable conjugation through irreversible chemistry. BioRay focuses on immune-mediated diseases that has developed an autoimmune and oncology portfolio consisting of six marketed products and over 10 clinical-stage drug candidates. Earlier this year, BioRay completed a $218 million strategic financing. In 2019, the company was spun out of Hisun Pharma, which sold a 58% BioRay stake for $540 million to private equity firm PAG. More details.....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital